These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22372867)

  • 21. Human radiolabeled mass balance studies: objectives, utilities and limitations.
    Penner N; Klunk LJ; Prakash C
    Biopharm Drug Dispos; 2009 May; 30(4):185-203. PubMed ID: 19544285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
    Lappin G; Seymour M
    Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving molecules using multi-objective optimization: applying to ADME/Tox.
    Ekins S; Honeycutt JD; Metz JT
    Drug Discov Today; 2010 Jun; 15(11-12):451-60. PubMed ID: 20438859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics.
    Brocks DR
    Biopharm Drug Dispos; 2006 Nov; 27(8):387-406. PubMed ID: 16944450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioanalysis young investigator: Pan Deng.
    Deng P
    Bioanalysis; 2012 May; 4(9):997-8. PubMed ID: 22612679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes.
    Sutherland JJ; Raymond JW; Stevens JL; Baker TK; Watson DE
    J Med Chem; 2012 Jul; 55(14):6455-66. PubMed ID: 22716080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron-catalysed tritiation of pharmaceuticals.
    Yu RP; Hesk D; Rivera N; Pelczer I; Chirik PJ
    Nature; 2016 Jan; 529(7585):195-9. PubMed ID: 26762456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using in vitro human tissues to predict pharmacokinetic properties.
    Huebert ND; Dasgupta M; Chen Y
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):69-74. PubMed ID: 14982150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of whole-body autoradioluminography in drug discovery for the quantification of tritium-labeled drug candidates.
    Potchoiba MJ; Nocerini MR
    Drug Metab Dispos; 2004 Oct; 32(10):1190-8. PubMed ID: 15377642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitigating permeability-mediated risks in drug discovery.
    Wang J; Skolnik S
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):171-87. PubMed ID: 20064074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Species differences in distribution and prediction of human V(ss) from preclinical data.
    Berry LM; Li C; Zhao Z
    Drug Metab Dispos; 2011 Nov; 39(11):2103-16. PubMed ID: 21852367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines.
    Alavijeh MS; Palmer AM
    IDrugs; 2004 Aug; 7(8):755-63. PubMed ID: 15334309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.
    Ings RM
    Bioanalysis; 2009 Oct; 1(7):1293-305. PubMed ID: 21083052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MALDI imaging mass spectrometry: bridging biology and chemistry in drug development.
    Castellino S; Groseclose MR; Wagner D
    Bioanalysis; 2011 Nov; 3(21):2427-41. PubMed ID: 22074284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Strategy of molecular drug design: hits, leads and drug candidates].
    Guo ZR
    Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery.
    Li C; Liu B; Chang J; Groessl T; Zimmerman M; He YQ; Isbell J; Tuntland T
    Drug Discov Today; 2013 Jan; 18(1-2):71-8. PubMed ID: 22982770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.